Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Intellia Therapeutics (NASDAQ:NTLA), a clinical-stage gene editing company specializing in CRISPR-based therapies, has granted inducement awards to six new employees under its 2024 Inducement Plan. The awards consist of 23,800 restricted stock units (RSUs) of Intellia's common stock.
The RSUs will vest in three equal installments on July 1 of 2026, 2027, and 2028, subject to continued employment. These awards, approved by Intellia's compensation committee, were granted outside the company's stockholder-approved equity incentive plans in accordance with Nasdaq Listing Rule 5635(c)(4).
Intellia Therapeutics (NASDAQ:NTLA), una società in fase clinica specializzata in terapie basate su CRISPR, ha assegnato premi di incentivo a sei nuovi dipendenti nell'ambito del suo Piano di Incentivo 2024. I premi consistono in 23.800 unità di azioni vincolate (RSU) delle azioni ordinarie di Intellia.
Le RSU matureranno in tre tranche uguali il 1° luglio 2026, 2027 e 2028, subordinatamente alla permanenza in servizio. Questi premi, approvati dal comitato per la remunerazione di Intellia, sono stati concessi al di fuori dei piani azionari approvati dagli azionisti, in conformità con la regola Nasdaq Listing Rule 5635(c)(4).
Intellia Therapeutics (NASDAQ:NTLA), una empresa en etapa clínica especializada en terapias basadas en CRISPR, ha otorgado premios de incentivo a seis nuevos empleados bajo su Plan de Incentivos 2024. Los premios consisten en 23,800 unidades de acciones restringidas (RSU) de las acciones comunes de Intellia.
Las RSU se consolidarán en tres cuotas iguales el 1 de julio de 2026, 2027 y 2028, sujeto a la continuidad del empleo. Estos premios, aprobados por el comité de compensación de Intellia, se concedieron fuera de los planes de incentivos de capital aprobados por los accionistas, de acuerdo con la norma Nasdaq Listing Rule 5635(c)(4).
Intellia Therapeutics (NASDAQ:NTLA)는 CRISPR 기반 치료법을 전문으로 하는 임상 단계 유전자 편집 회사로, 2024년 유인 계획에 따라 6명의 신규 직원에게 유인 보상을 부여했습니다. 이 보상은 Intellia의 보통주 23,800개의 제한 주식 단위(RSU)로 구성됩니다.
RSU는 계속 고용 조건 하에 2026년, 2027년, 2028년 7월 1일에 각각 3등분하여 권리가 확정됩니다. 이 보상은 Intellia 보상위원회의 승인을 받았으며, Nasdaq 상장 규칙 5635(c)(4)에 따라 주주 승인 주식 인센티브 계획 외부에서 부여되었습니다.
Intellia Therapeutics (NASDAQ:NTLA), une société en phase clinique spécialisée dans les thérapies basées sur CRISPR, a accordé des récompenses d'incitation à six nouveaux employés dans le cadre de son Plan d'Incitation 2024. Ces récompenses consistent en 23 800 unités d'actions restreintes (RSU) des actions ordinaires d'Intellia.
Les RSU seront acquises en trois versements égaux les 1er juillet 2026, 2027 et 2028, sous réserve de la poursuite de l'emploi. Ces récompenses, approuvées par le comité de rémunération d'Intellia, ont été octroyées en dehors des plans d'incitation en actions approuvés par les actionnaires, conformément à la règle Nasdaq Listing Rule 5635(c)(4).
Intellia Therapeutics (NASDAQ:NTLA), ein klinisch fortgeschrittenes Unternehmen für Genom-Editing mit Schwerpunkt auf CRISPR-basierten Therapien, hat unter seinem Anreizplan 2024 sechs neuen Mitarbeitern Anreizprämien gewährt. Die Prämien bestehen aus 23.800 Restricted Stock Units (RSUs) von Intellias Stammaktien.
Die RSUs werden in drei gleichen Raten am 1. Juli 2026, 2027 und 2028 fällig, vorbehaltlich einer fortgesetzten Beschäftigung. Diese Prämien, genehmigt vom Vergütungsausschuss von Intellia, wurden außerhalb der von den Aktionären genehmigten Aktienanreizpläne des Unternehmens gemäß der Nasdaq-Listing-Regel 5635(c)(4) gewährt.
- None.
- None.
CAMBRIDGE, Mass., July 07, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on July 1, 2025, it awarded an inducement grant to six new employees under Intellia’s 2024 Inducement Plan as a material inducement to employment.
The inducement grant consisted of time-based restricted stock units (“RSUs”) for 23,800 shares of Intellia’s common stock, with one-third of such RSUs vesting on July 1, 2026, 2027 and 2028.
All equity vesting is subject to each employee’s continued service as an employee of, or other service provider to, Intellia through the applicable vesting dates.
All of the above-described awards were granted outside of Intellia’s stockholder-approved equity incentive plans pursuant to Intellia’s 2024 Inducement Plan, which was adopted by the board of directors in June 2024. These awards were approved by Intellia’s compensation committee as a material inducement to entering into employment with Intellia in accordance with Nasdaq Listing Rule 5635(c)(4).
About Intellia Therapeutics
Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies. Since its inception, Intellia has focused on leveraging gene editing technology to develop novel, first-in-class medicines that address important unmet medical needs and advance the treatment paradigm for patients. Intellia’s deep scientific, technical and clinical development experience, along with its people, is helping set the standard for a new class of medicine. To harness the full potential of gene editing, Intellia continues to expand the capabilities of its CRISPR-based platform with novel editing and delivery technologies. Learn more at intelliatx.com and follow us @intelliatx.
Intellia Contacts:
Investors:
Brittany Chaves
Senior Manager, Investor Relations
brittany.chaves@intelliatx.com
FAQ
What type of inducement grants did Intellia Therapeutics (NTLA) announce in July 2025?
How will the RSUs vest for Intellia Therapeutics' new employees?
Under which plan were Intellia's inducement grants awarded?
What is Intellia Therapeutics' main business focus?
